BioSpace News Archive

Novel Phase 3 Trial Design to Evaluate Bemnifosbuvir as Monotherapy and Combination Antiviral Therapy for COVID-19.

Canonic Ltd., focused on the development of medical grade cannabis products and a wholly owned subsidiary of Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), announced today that it has signed a non-exclusive licensing agreement with leading Portugal-based cannabis cultivation and manufacturing company, GroVida Lda

Numinus Wellness is pleased to provide an update on the integration of the Novamin acquisition, which completed on June 10, 2022.

HHS Technology Group, LLC™ (HTG); Datavant, the leader in helping organizations securely connect health data; and Mathematica announced today they are collaborating to offer public and private sector access to invaluable resources to fight the invisible epidemic of chronic kidney disease (CKD) and long-term COVID-19.

BioStem Technologies Inc. today announced the publication of a guidance paper on growth factor standardization in a recent open-accessarticle in Health Science Reports.

Annovis Bio (“Annovis” or the “Company”), a clinical-stage drug platform company addressing neurodegenerative diseases, announced today the publication of three granted US patents – US11400075 ( link ), US11376238 ( link ), and US11382893 ( link ).

Elidah Inc., a growing medical solutions company that focuses on delivering FDA-cleared, clinically-proven treatment devices for difficult-to-treat female health urinary conditions announced that it has signed a national agreement with VGM & Associates.

Cidara Therapeutics, Inc. today announced the initiation of its Phase 2a trial to evaluate the pre-exposure prophylactic activity of CD388 against influenza virus. CD388 is a highly potent, long-acting antiviral designed to deliver universal prevention of seasonal and pandemic influenza.

Enlivex Therapeutics Ltd. announced that Company management will be presenting at the following investor and media conferences in September.

Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today announced that the first subjects have been dosed in a Phase 1 clinical trial of UB-313, a vaccine targeting calcitonin gene-related peptide (CGRP), for the preventive treatment of migraine.